Evidence map›Paper›PMID 26423935›Full record

ReviewBrain research2016

Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases.

Ashok K Shetty, Adrian Bates

Open access · greenAbstract readReview
In one paragraph

Review in Brain research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Glutamate measurements using edited MRS.Magnetic resonance in medicine · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Photopotentiation of the GABAProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ashok K ShettyInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, United States; Research Service, Olin E. Teague Veterans׳ Medical Center, Central Texas Veterans Health Care System, Temple, TX, United States; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center College of Medicine, College Station, TX, United States. Electronic address: shetty@medicine.tamhsc.edu.
Adrian BatesInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, United States; Research Service, Olin E. Teague Veterans׳ Medical Center, Central Texas Veterans Health Care System, Temple, TX, United States; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center College of Medicine, College Station, TX, United States.
Texas A&M Health Science Center · US

Funding

Combined NSC Grafting and Neurogenic Drug Therapy for Temporal Lobe EpilepsyI01BX002351 · VA · OLIN TEAGUE VETERANS CENTER · PI SHETTY, ASHOK K · 2015 to 2018
–
BLR&D Research Career Scientist AwardIK6BX003612 · VA · OLIN TEAGUE VETERANS CENTER · PI SHETTY, ASHOK K · 2017 to 2019
–
BLRD VA I01 BX002351BLRD VA IK6 BX003612
6 · The paper itself

Abstract

Several neurological and psychiatric disorders present hyperexcitability of neurons in specific regions of the brain or spinal cord, partly because of some loss and/or dysfunction of gamma-amino butyric acid positive (GABA-ergic) inhibitory interneurons. Strategies that enhance inhibitory neurotransmission in the affected brain regions may therefore ease several or most deficits linked to these disorders. This perception has incited a huge interest in testing the efficacy of GABA-ergic interneuron cell grafting into regions of the brain or spinal cord exhibiting hyperexcitability, dearth of GABA-ergic interneurons or impaired inhibitory neurotransmission, using preclinical models of neurological and psychiatric disorders. Interneuron progenitors from the embryonic ventral telencephalon capable of differentiating into diverse subclasses of interneurons have particularly received much consideration because of their ability for dispersion, migration and integration with the host neural circuitry after grafting. The goal of this review is to discuss the premise, scope and advancement of GABA-ergic cell therapy for easing neurological deficits in preclinical models of schizophrenia, chronic neuropathic pain, Alzheimer's disease and Parkinson's disease. As grafting studies in these prototypes have so far utilized either primary cells from the embryonic medial and lateral ganglionic eminences or neural progenitor cells expanded from these eminences as donor material, the proficiency of these cell types is highlighted. Moreover, future studies that are essential prior to considering the possible clinical application of these cells for the above neurological conditions are proposed. Particularly, the need for grafting studies utilizing medial ganglionic eminence-like progenitors generated from human pluripotent stem cells via directed differentiation approaches or somatic cells through direct reprogramming methods are emphasized. This article is part of a Special Issue entitled SI: PSC and the brain.

Indexed as

Alzheimer DiseaseCell- and Tissue-Based TherapyCell DifferentiationGABAergic NeuronsHumansInterneuronsNeuralgiaNeural Stem CellsParkinson DiseasePluripotent Stem CellsSchizophreniaAlzheimer׳s diseaseGABA-ergic interneuronsMedial ganglionic eminenceNeural cell graftsPainParkinson׳s diseaseSchizophreniaStem cell therapy

Identifiers

PMID26423935
PMCPMC5313260
OpenAlexW1808186746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.